{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:38Z","timestamp":1792172378972,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2023JJ30900"],"award-info":[{"award-number":["2023JJ30900"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2022JJ70084"],"award-info":[{"award-number":["2022JJ70084"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck Sharp & Dohme","award":["100759"],"award-info":[{"award-number":["100759"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-52233-z","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:44:36Z","timestamp":1778593476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ceftazidime\u2013avibactam drives mutations, insertion, or overexpression in blaKPC-2 and enhances biofilm-forming ability of KPC-producing Klebsiella pneumoniae"],"prefix":"10.1038","volume":"16","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"52233_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2024.100414","volume":"26","author":"MW Gach","year":"2024","unstructured":"Gach, M. W. et al. Antimicrobial resistance among common bacterial pathogens in Indonesia: A systematic review. Lancet. Reg. Health. Southeast. Asia. 26, 100414 (2024).","journal-title":"Lancet. Reg. Health. Southeast. Asia."},{"key":"52233_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae052","volume":"6","author":"X Qin","year":"2024","unstructured":"Qin, X. et al. Antimicrobial resistance of clinical bacterial isolates in China: Current status and trends. JAC. Antimicrob. Resist. 6, dlae052 (2024).","journal-title":"JAC. Antimicrob. Resist."},{"key":"52233_CR3","doi-asserted-by":"crossref","unstructured":"Chen, Y. C., Tsai, I. T., Lai, C. H., Lin, K. H. & Hsu, Y. C. Risk factors and outcomes of community-acquired carbapenem-resistant Klebsiella pneumoniae infection in elderly patients. Antibiotics (Basel). 13,\u00a0(2024).","DOI":"10.3390\/antibiotics13030282"},{"key":"52233_CR4","unstructured":"World Health Organization. https:\/\/www.who.int\/news\/item\/17-05-2024-who-updates-list-of-drug-resistant-bacteria-most-threatening-to-human-health (2024)."},{"key":"52233_CR5","doi-asserted-by":"publisher","first-page":"ofaf005","DOI":"10.1093\/ofid\/ofaf005","volume":"12","author":"HS Sader","year":"2025","unstructured":"Sader, H. S. et al. Antimicrobial Susceptibility, and Molecular Characterization of Carbapenem-Resistant Enterobacterales Stratified by United States Census Divisions: Results From the INFORM Program (2018\u20132022). Open. Forum Infect. Dis. 12, ofaf005 (2025).","journal-title":"Open. Forum Infect. Dis."},{"key":"52233_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","volume":"22","author":"WR Miller","year":"2024","unstructured":"Miller, W. R. & Arias, C. A. ESKAPE pathogens: Antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat. Rev. Microbiol. 22, 598\u2013616 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"52233_CR7","doi-asserted-by":"crossref","unstructured":"Tamma, P. D. et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect. Dis. (2023).","DOI":"10.1093\/cid\/ciad428"},{"key":"52233_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-020-00829-z","volume":"9","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: A surveillance study from the ATLAS program (2012\u20132016). Antimicrob. Resist. Infect. Control. 9, 166 (2020).","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"52233_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106679","volume":"60","author":"YL Lee","year":"2022","unstructured":"Lee, Y. L., Ko, W. C. & Hsueh, P. R. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime\/avibactam, meropenem\/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int. J. Antimicrob. Agents. 60, 106679 (2022).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"52233_CR10","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jac\/dkz026","volume":"74","author":"P Hemarajata","year":"2019","unstructured":"Hemarajata, P. & Humphries, R. M. Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J. Antimicrob. Chemother. 74, 1241\u20131243 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"52233_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00008-23","volume":"36","author":"L Ding","year":"2023","unstructured":"Ding, L. et al. Klebsiella pneumoniae carbapenemase variants: The new threat to global public health. Clin. Microbiol. Rev. 36, e0000823 (2023).","journal-title":"Clin. Microbiol. Rev."},{"key":"52233_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107411","volume":"65","author":"P Zhou","year":"2025","unstructured":"Zhou, P. et al. Characterization of a novel KPC-2 variant, KPC-228, conferring resistance to ceftazidime-avibactam in an ST11-KL64 hypervirulent Klebsiella pneumoniae. Int. J. Antimicrob. Agents. 65, 107411 (2025).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"52233_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101205","volume":"79","author":"X Li","year":"2025","unstructured":"Li, X., Zhou, L. & Huang, H. Dynamic evolution of KPC-230-mediated resistance to ceftazidime-avibactam during the treatment of carbapenem-resistant Klebsiella pnenmoniae. Drug Resist. Updat. 79, 101205 (2025).","journal-title":"Drug Resist. Updat."},{"key":"52233_CR14","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/jac\/dkx066","volume":"72","author":"Z Shen","year":"2017","unstructured":"Shen, Z. et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime\/avibactam in KPC-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 72, 1930\u20131936 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"52233_CR15","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1080\/22221751.2021.1984182","volume":"10","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae. Emerg. Microbes Infect. 10, 2042\u20132051 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"52233_CR16","first-page":"3287","volume":"14","author":"J Li","year":"2021","unstructured":"Li, J. et al. Clonal Dissemination of Multiple Carbapenemase Genes in Carbapenem-Resistant Enterobacterales Mediated by Multiple Plasmids in China. Infect. Drug Resist. 14, 3287\u20133295 (2021).","journal-title":"Infect. Drug Resist."},{"key":"52233_CR17","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 34th ed Clin Lab. Stand. Inst (2024)."},{"key":"52233_CR18","unstructured":"The US Food and Drug Administration (USFDA). Tigecycline-Injection products [EB\/OL]. 01-26 https:\/\/www.fda.gov\/drugs\/development-resources\/tigec-ycline-injection-products (2023)."},{"key":"52233_CR19","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints-breakpoints and guidance [EB\/OL]. 01-02. https:\/\/w-ww.eucast.org\/clinical_breakpoints (2023)."},{"key":"52233_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002158","volume":"7","author":"E Gullberg","year":"2011","unstructured":"Gullberg, E. et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog. 7, e1002158 (2011).","journal-title":"PLoS Pathog."},{"key":"52233_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01379-18","author":"F Sanz-Garc\u00eda","year":"2018","unstructured":"Sanz-Garc\u00eda, F., Hernando-Amado, S. & Mart\u00ednez, J. L. Mutation-driven evolution of Pseudomonas aeruginosa in the presence of either ceftazidime or ceftazidime-avibactam. Antimicrob. Agents Chemother. 62,\u00a0(2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52233_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.809542","volume":"11","author":"L Sun","year":"2021","unstructured":"Sun, L. et al. A novel tigecycline adjuvant ML-7 reverses the susceptibility of tigecycline-resistant Klebsiella pneumoniae. Front. Cell. Infect. Microbiol. 11, 809542 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"52233_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/978-1-4939-0473-0_48","volume":"1149","author":"BM Coffey","year":"2014","unstructured":"Coffey, B. M. & Anderson, G. G. Biofilm formation in the 96-well microtiter plate. Methods Mol. Biol. 1149, 631\u2013641 (2014).","journal-title":"Methods Mol. Biol."},{"key":"52233_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/21505594.2020.1809322","volume":"11","author":"C Liu","year":"2020","unstructured":"Liu, C. et al. Hypervirulent Klebsiella pneumoniae is emerging as an increasingly prevalent K. pneumoniae pathotype responsible for nosocomial and healthcare-associated infections in Beijing, China. Virulence. 11, 1215\u20131224 (2020).","journal-title":"Virulence"},{"key":"52233_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2366354","volume":"13","author":"Z Zhao","year":"2024","unstructured":"Zhao, Z. et al. A novel small RNA PhaS contributes to Polymyxin B-heteroresistance in carbapenem-resistant Klebsiella pneumoniae. Emerg. Microbes Infect. 13, 2366354 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"52233_CR26","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53, D672-d677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"52233_CR27","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"52233_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"52233_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-021-00998-8","volume":"52","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. LsrR, the effector of AI-2 quorum sensing, is vital for the H2O2 stress response in mammary pathogenic Escherichia coli. Vet. Res. 52, 127 (2021).","journal-title":"Vet. Res."},{"key":"52233_CR30","doi-asserted-by":"publisher","first-page":"e0174454","DOI":"10.1371\/journal.pone.0174454","volume":"12","author":"M L\u00f3pez","year":"2017","unstructured":"L\u00f3pez, M. et al. Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme. PLoS One. 12, e0174454 (2017).","journal-title":"PLoS One"},{"key":"52233_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00955-22","volume":"10","author":"X Li","year":"2022","unstructured":"Li, X. et al. Increased expression and amplification of blaKPC-2 contributes to resistance to Ceftazidime\/Avibactam in a Sequence Type 11 carbapenem-resistant Klebsiella pneumoniae strain. Microbiol. Spectr. 10, e0095522 (2022).","journal-title":"Microbiol. Spectr."},{"key":"52233_CR32","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields, R. K. et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin. Infect. Dis. 63, 1615\u20131618 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"52233_CR33","doi-asserted-by":"publisher","first-page":"S436","DOI":"10.1093\/cid\/ciaa1521","volume":"71","author":"Q Shi","year":"2020","unstructured":"Shi, Q. et al. Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China. Clin. Infect. Dis. 71, S436\u2013s439 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"52233_CR34","doi-asserted-by":"publisher","first-page":"727946","DOI":"10.3389\/fmicb.2021.727946","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. In vivo Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible Klebsiella pneumoniae Isolate With KPC-33 Carbapenemase. Front. Microbiol. 12, 727946 (2021).","journal-title":"Front. Microbiol."},{"key":"52233_CR35","doi-asserted-by":"crossref","unstructured":"Ding, L. et al. Ceftazidime-Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing Klebsiella pneumoniae. Antibiotics (Basel). 11, (2022).","DOI":"10.3390\/antibiotics11050604"},{"key":"52233_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jgar.2019.11.007","volume":"22","author":"\u00c1 Cano","year":"2020","unstructured":"Cano, \u00c1. et al. Use of carbapenems in the combined treatment of emerging ceftazidime\/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature. J. Glob Antimicrob. Resist. 22, 9\u201312 (2020).","journal-title":"J. Glob Antimicrob. Resist."},{"key":"52233_CR37","doi-asserted-by":"publisher","first-page":"e0044722","DOI":"10.1128\/aac.00447-22","volume":"66","author":"CA Hobson","year":"2022","unstructured":"Hobson, C. A. et al. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview. Antimicrob. Agents Chemother. 66, e0044722 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52233_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054767","author":"S Corcione","year":"2023","unstructured":"Corcione, S. et al. Ceftazidime-avibactam (C\/A) resistant, meropenem sensitive KPC-producing Klebsiella pneumoniae in ICU setting: We are what we are treated with?. Int. J. Mol. Sci. 24,\u00a0(2023).","journal-title":"Int. J. Mol. Sci."},{"key":"52233_CR39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00989-17","author":"K Nelson","year":"2017","unstructured":"Nelson, K. et al. Resistance to Ceftazidime-Avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob. Agents Chemother. 61,\u00a0(2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52233_CR40","doi-asserted-by":"publisher","first-page":"124e121","DOI":"10.1016\/j.cmi.2019.08.020","volume":"26","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin. Microbiol. Infect. 26, 124e121\u2013124e124 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"52233_CR41","doi-asserted-by":"crossref","unstructured":"Huang, J. et al. Genetic Factors Associated with Enhanced blaKPC Expression in Tn3\/Tn4401 Chimeras. Antimicrob Agents Chemother. 64, (2020).","DOI":"10.1128\/AAC.01836-19"},{"key":"52233_CR42","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1128\/AAC.00952-15","volume":"59","author":"MJ Choi","year":"2015","unstructured":"Choi, M. J. & Ko, K. S. Loss of hypermucoviscosity and increased fitness cost in colistin-resistant Klebsiella pneumoniae sequence type 23 strains. Antimicrob. Agents Chemother. 59, 6763\u20136773 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52233_CR43","doi-asserted-by":"publisher","first-page":"e0042324","DOI":"10.1128\/msphere.00423-24","volume":"9","author":"V Capitani","year":"2024","unstructured":"Capitani, V. et al. In vivo evolution to hypermucoviscosity and ceftazidime\/avibactam resistance in a liver abscess caused by Klebsiella pneumoniae sequence type 512. mSphere. 9, e0042324 (2024).","journal-title":"mSphere"},{"key":"52233_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12866-024-03508-w","volume":"24","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae accompanied hypermucoviscosity acquisition. BMC Microbiol. 24, 439 (2024).","journal-title":"BMC Microbiol."},{"key":"52233_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9010053","author":"L Cui","year":"2020","unstructured":"Cui, L. et al. CRISPR-cas3 of Salmonella upregulates bacterial biofilm formation and virulence to host cells by targeting quorum-sensing systems. Pathogens.\u00a09,\u00a0(2020).","journal-title":"Pathogens"},{"key":"52233_CR46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1021\/acsinfecdis.3c00591","volume":"10","author":"R Cui","year":"2024","unstructured":"Cui, R. et al. Dronedarone enhances the antibacterial activity of Polymyxin B and inhibits the quorum sensing system by interacting with LuxS. ACS Infect. Dis. 10, 961\u2013970 (2024).","journal-title":"ACS Infect. Dis."},{"key":"52233_CR47","doi-asserted-by":"publisher","first-page":"113844","DOI":"10.1016\/j.isci.2025.113844","volume":"28","author":"J Li","year":"2025","unstructured":"Li, J. et al. Exposure to ceftazidime-avibactam induced antimicrobial resistance and enhanced virulence in a Klebsiella pneumoniae strain. iScience. 28, 113844 (2025).","journal-title":"iScience"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52233-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52233-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52233-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:47:22Z","timestamp":1783900042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52233-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52233"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52233-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Italic' removed-->Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Clinical Research Medical Ethics Subcommittee of the Medical Ethics Committee of Xiangya Hospital, Central South University (ID 202209541). All methods were performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Written informed consent was obtained from the participants enrolled in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent\u00a0<!--Emphasis Type='Bold' removed-->statement"}}],"article-number":"21746"}}